Zealand Pharma A/S

BATS-CHIXE:ZEALC Stock Report

Market Cap: DKK 41.4b

Zealand Pharma Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Adam Steensberg

Chief executive officer

DKK 42.3m

Total compensation

CEO salary percentage21.3%
CEO tenure3yrs
CEO ownership0.05%
Management average tenure3.2yrs
Board average tenure9.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Adam Steensberg's remuneration changed compared to Zealand Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024DKK 42mDKK 9m

-DKK 1b

Sep 30 2024n/an/a

-DKK 1b

Jun 30 2024n/an/a

-DKK 712m

Mar 31 2024n/an/a

-DKK 739m

Dec 31 2023DKK 25mDKK 6m

-DKK 704m

Sep 30 2023n/an/a

-DKK 760m

Jun 30 2023n/an/a

-DKK 986m

Mar 31 2023n/an/a

-DKK 1b

Dec 31 2022DKK 19mDKK 4m

-DKK 966m

Sep 30 2022n/an/a

-DKK 855m

Jun 30 2022n/an/a

-DKK 845m

Mar 31 2022n/an/a

-DKK 608m

Dec 31 2021DKK 10mDKK 3m

-DKK 755m

Sep 30 2021n/an/a

-DKK 925m

Jun 30 2021n/an/a

-DKK 1b

Mar 31 2021n/an/a

-DKK 909m

Dec 31 2020DKK 7mDKK 3m

-DKK 669m

Sep 30 2020n/an/a

-DKK 660m

Jun 30 2020n/an/a

-DKK 545m

Mar 31 2020n/an/a

-DKK 624m

Dec 31 2019DKK 7mDKK 3m

-DKK 572m

Compensation vs Market: Adam's total compensation ($USD6.16M) is above average for companies of similar size in the UK market ($USD3.52M).

Compensation vs Earnings: Adam's compensation has increased whilst the company is unprofitable.

CEO

Adam Steensberg (50 yo)

3yrs

Tenure

DKK 42,264,000

Compensation

Mr. Adam Sinding Steensberg, M.D., serves as President and Chief Executive Officer at Zealand Pharma A/S since March 30, 2022. He had been an Executive Vice President of Research & Development and Chief Me...

Leadership Team

NamePositionTenureCompensationOwnership
Adam Steensberg
President & CEO3yrsDKK 42.26m0.048%
DKK 19.9m
Henriette Wennicke
EVP & CFO2.3yrsDKK 16.84m0.0049%
DKK 2.0m
Ivan Moller
Executive VP & COO7yrsno data0.064%
DKK 26.6m
Ravinder Chahil
EVP & General Counsel3.2yrsno data0.010%
DKK 4.3m
Christina Bredal
Executive VP & Chief People Officer3.9yrsno data0.0095%
DKK 3.9m
Jens Mikkelsen
Head of Molecular Pharmacologyno datano datano data
David Kendall
Executive VP4.5yrsno data0.013%
DKK 5.4m
Eric Cox
Executive VP & Chief Commercial Officerless than a yearno datano data
Miriam Katz
Assistant Secretaryno datano datano data
Anna Krassowska
Vice President of Investor Relations & Corporate Communicationsno datano datano data

3.2yrs

Average Tenure

52yo

Average Age

Experienced Management: ZEALC's management team is considered experienced (3.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Leonard Kruimer
Independent Director5.9yrsDKK 1.38m0.022%
DKK 9.2m
Alf Gunnar Nicklasson
Independent Chairman of the Board9.9yrsDKK 2.87m0.026%
DKK 10.9m
Kirsten Drejer
Independent Vice Chairman6.9yrsDKK 1.38m0.012%
DKK 5.2m
Ake Lernmark
Member of Advisory Board13.3yrsno datano data
Gudmund Korsgard
Board Observerno datano datano data
Jeffrey Berkowitz
Independent Director5.9yrsDKK 1.38m0.012%
DKK 4.8m
Bernard Charbonnel
Member of Advisory Board13.3yrsno datano data
Richard Pratley
Member of Advisory Board13.3yrsno datano data
Paul Dorian
Member of Advisory Board13.3yrsno datano data
Gert Van Assche
Member of Advisory Board13.3yrsno datano data
Bernadette Connaughton
Independent Director5.9yrsDKK 1.38m0.012%
DKK 5.0m
Nikolaj Barfoed Beck
Employee Representative Director4.9yrsDKK 611.00k0.0067%
DKK 2.8m

9.9yrs

Average Tenure

66.5yo

Average Age

Experienced Board: ZEALC's board of directors are considered experienced (9.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/15 12:59
End of Day Share Price 2025/03/13 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Zealand Pharma A/S is covered by 25 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Laura HindleyBerenberg
Kerry HolfordBerenberg
Charlie HaywoodBofA Global Research